Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.

ABSTRACT:

Background

Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend routine prophylactic coverage with granulocyte colony-stimulating factor (G-CSF)-such as pegfilgrastim-for most patients receiving chemotherapy with an intermediate to high risk for FN. Patterns of pegfilgrastim prophylaxis during the chemotherapy course and associated FN risks in US clinical practice have not been well characterized.

Methods

A retrospective cohort design and data from two commercial healthcare claims repositories (01/2010-03/2016) and Medicare Claims Research Identifiable Files (01/2007-09/2015) were employed. Study population included patients who had non-metastatic breast cancer or non-Hodgkin's lymphoma and received inter

SUBMITTER: Weycker D 

PROVIDER: S-EPMC6688232 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature